Skip to Content

PerkinElmer Inc PKI Stock Quote

| Rating as of

Morningstar‘s Stock Analysis PKI

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat PerkinElmer Aims for Higher Margins Through Portfolio Transformation

Julie Utterback, CFA Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback, CFA |

With myriad acquisitions in the past few years, PerkinElmer has been in a constant state of evolution since 2016 when the company made the transition into two new business segments, diagnostics and discovery and analytical solutions, or DAS. With the announcement of the divestment of its Applied, Food, and Enterprise Services business planned for early 2023, the company will operate under a new name and will focus solely on the life sciences and diagnostics business. We are confident that the firm's renewed strategic focus on improving its diagnostic product mix and life sciences business will maintain returns over cost of capital and produce tangible benefits for shareholders in the long run.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics PKI

Company Profile PKI

Business Description

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

940 Winter Street
Waltham, MA, 02451
T +1 781 663-6900
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Jan 2, 2023
Employees 16,700